Browse EX-10 agreements

Execution Version

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

THIRD AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENT

    ThisThird Amendment to Collaboration, Option and License Agreement (this “ThirdAmendment”), dated August 26, 2026 (the “Third Amendment Effective Date”), is by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).

RECITALS

WHEREAS, Gilead and Nurix are parties to that certain Collaboration, Option and License Agreement, dated June 10, 2019, as amended by that certain First Amendment and Second Amendment to Collaboration, Option and License Agreement dated August 13, 2019 and September 9, 2022 respectively, by and between the Parties (as so amended the “Agreement”); and

…

Execution Version

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

License and Collaboration Agreement

This license and collaboration agreement is entered into with effect as of the Effective Date (as defined below)

by and between

F. Hoffmann-La Roche Ltd

with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“FHLR”)

and

Genentech, Inc.

with an office and place of business at 1 DNA Way, South San Francisco, CA 94080, United States (“Genentech”; FHLR and Genentech collectively referred to as “Roche”), on the one hand,

and

Nurix Therapeutics Inc.

with an office and place of business at 1600 Sierra Point Parkway
Brisbane, CA 94005 (“Nurix”), on the other hand.

---

TABLE OF CONTENTS

Page

…

** **

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

** **

Principal Amount: US$55,637.41	Dated as of August 15, 2026

** **

…

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

** **

Principal Amount: US$55,637.41	Dated as of September 15, 2026

…

AMENDMENT TO AT-THE-MARKET ISSUANCE SALES AGREEMENT

DATED JUNE 18, 2026

This amendment (the “Amendment”) to the At-The-Market Issuance Sales Agreement dated June 18, 2026 (the “Agreement”), entered into by and between Hyperscale Data, Inc., a Delaware corporation (the “Company”) and Spartan Capital Securities, LLC (the “Agent”) is dated October 9, 2026. All capitalized terms in this Amendment and not defined herein shall have the meanings ascribed to such terms in the Agreement.

WHEREAS, the Company and the Agent desire to amend the Agreement.

NOW, THEREFORE, in consideration of the foregoing and intending to be legally bound hereby, the parties hereto agree as follows:

	1.	The first paragraph of Section 1 is hereby deleted and replaced in its entirety by the following:

…

SUBSIDIARY GUARANTEE

** **

THIS SUBSIDIARY GUARANTEE, dated as of October 9, 2026 (this “Guarantee”), is made by each of DNA Logix, Inc., a Utah corporation, Idaho Molecular, Inc., an Idaho corporation and Advanced Conceptions, Inc., a Utah corporation (collectively, the “Existing Subsidiaries”), each a direct subsidiary of Co-Diagnostics Inc., a Utah corporation (the “Company”) and any other Person who is formed or acquired by the Company or any of the Existing Subsidiaries (together with any other entity that may become a party hereto as an Additional Subsidiary Guarantor as provided in Annex 1 hereto) (individually a “Subsidiary Guarantor” and collectively the “Subsidiary Guarantors”), in favor of J.J. Astor & Co., a Utah corporation (acting for itself and together with its participating lender or lender, each the “Lender”).

W I T N E S S E T H:

** **

…

THIS ATM WATERFALL DISTRIBUTION AGREEMENT (“Agreement”) is made and entered into as of October 9, 2026 by and among Co-Diagnostics, Inc., a Utah corporation (the “Company”), J.J. Astor & Co., a Utah corporation (“Astor” or the “Lender”) and Maxim Group LLC (the “ATM Sales Agent”). The Company, the Lender and the ATM Sales Agent are hereinafter sometimes individually referred to as a “Party” and collectively as the “Parties.”

R E C I T A L S:

WHEREAS, the Company and the Lender have entered into a loan agreement dated as of October 9, 2026 (the “Loan Agreement”). Any capitalized terms used but not defined in this Agreement shall have the meanings ascribed thereto in the Loan Agreement;

…

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 9, 2026 (the “Agreement Date”) by and between Co-Diagnostics, Inc., a Utah corporation (the “Company”), and J.J. Astor & Co., a Utah corporation (“Astor”), acting on behalf of itself and each participating lender (individually and collectively with Astor, the “Lender”).

This Agreement is made pursuant to the Loan Agreement, dated as of the date hereof, between the Company and the Lender (the “Loan Agreement”).

The Company and the Lender hereby agree as follows:

1.	Definitions.

Capitalized terms used and not otherwise defined herein that are defined in the Loan Agreement or the Notes shall have the meanings given such terms in the Loan Agreement or the Notes. As used in this Agreement, the following terms shall have the following meanings:

“Closing Date” shall mean the Closing Date of the Initial Loan as defined in the Loan Agreement.

…

LOAN AGREEMENT

** **

This Loan Agreement (this “Agreement”) is dated as of October 9, 2026 (the “Agreement Date”) and is made and entered into between Co-Diagnostics, Inc., a Utah corporation (the “Company”), and J.J. Astor & Co., a Utah corporation ( “Astor”), acting on behalf of itself and one or more participating lender or lenders to whom Astor may, in the exercise of its sole discretion, assign and transfer participations of up to fifty percent (50%) in the Loans and the Notes (together with Astor, the “Lender”).

**WHEREAS, **the Company wishes to borrow the sum of up to Three Million One Hundred Thousand ($3,100,000) Dollars in two tranches (the “Loans”) of Two Million One Hundred Thousand ($2,100,000) Dollars (the “Initial Loan”) and, commencing sixty (60) days after the Agreement Date, an additional One Million ($1,000,000) Dollars (the “Additional Loan”) which the Company may elect to borrow and, absent a Material Adverse Effect or an Event of Default (as defined in the Notes) the Lender shall fund;

…

** **

Exhibit 10.6

** **

PLACEMENT AGENCY AGREEMENT

** **

October 9, 2026

Co-Diagnostics, Inc.

2401 S. Foothill Dr., Suite D

Salt Lake City, Utah 84109

Attention: Dwight H. Egan, Chief Executive Officer

Dear Mr. Egan:

This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Co-Diagnostics, Inc., a Utah corporation (collectively with its owned or controlled subsidiaries, the “Company”), that Maxim shall serve as the exclusive placement agent for the Company in connection with the proposed placement (the “Placement”) of a senior secured convertible note (the “Note”). The Placement Agent agrees to solicit offers to purchase the Note on a “reasonable best efforts” basis. The terms of the Placement shall be mutually agreed upon by the Company, Maxim and the purchasers of the Note (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein shall be construed as Maxim having the power or authority to bind the Company or any Purchaser or shall constitute an obligation of the Compa

…

PLEDGE AND SECURITY AGREEMENT

THIS PLEDGE AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of October 9, 2026, is made and entered into by and among (x) Co-Diagnostics, Inc., a Utah corporation (the “Company”); (y) DNA Logix, Inc., a Utah corporation, Idaho Molecular, Inc., an Idaho corporation and Advanced Conceptions, Inc., a Utah corporation (collectively, the “Existing Subsidiaries”),(z) each other Person who becomes a party to this Agreement by execution of a joinder in the form of Exhibit A attached hereto, which shall include all other direct or indirect Subsidiaries of the Company hereafter formed or acquired after the date hereof for so long as this Agreement remains in effect (the “Additional Subsidiaries” and together with the Company and the Existing Subsidiaries hereinafter sometimes referred to individually as a “Debtor” and, collectively, as the “Debtors”), on the one hand, and J.J. Astor & Co., a Utah corporation (“Astor”) acting on behalf of itself and e

…

SEPARATION AGREEMENT

This Separation Agreement (this “Agreement”) is made and entered into as of October 11, 2026 (the “Effective Date”), by and between Bausch + Lomb Corporation, a corporation existing under the laws of Canada (the “Company”), and Brenton L. Saunders (the “Executive”). The Company and the Executive are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.

RECITALS

WHEREAS, the Executive and the Company are parties to an Employment Agreement dated February 14, 2023, as amended by an Amendment to Employment Agreement dated July 21, 2025 (as so amended, the “Employment Agreement”), pursuant to which the Executive has served as Chairman of the Board and is currently a Director and Chief Executive Officer of the Company;

WHEREAS, the Executive and the Company desire to enter into this Agreement to document the terms and conditions of the Executive’s termination of employment, effective as of the Separation Date (as defined below); and

…